Sanofi targets 70% of endotoxin tests without horseshoe crab blood by 2030
- Sanofi plans to replace horseshoe crab blood-derived reagents with synthetic alternatives in 70% of quality-control endotoxin tests by year-end 2030.
- All new product launches will use synthetic testing methods by the same deadline, reducing reliance on natural resources.
- A nature-risk assessment identified four critical natural raw materials across operations and the value chain; expected financial exposure is negligible.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.